On May 27, 2025, Ascendis Pharma A/S held its Annual General Meeting where shareholders voted on key items, including carrying forward a consolidated loss of EUR 378.1 million from 2024 and approving the election of board members and auditors. The meeting saw 91.27% shareholder participation, with significant resolutions passed for management and capital structure changes.